What companies are tomorrow's big winners? In our ongoing series, I'm chatting with Fool analysts and advisors to discover the stocks they're watching and the catalysts that would signal it's time to buy.
Today, Motley Fool Special Ops senior analyst Mike Olsen shares two companies on his watchlist and one that he grabbed for himself. (For your convenience, you can now create your own version at MyWatchlist.com, your free customized hub to follow the performance and Fool coverage of the companies you care about.)
Mike likes a mess. If there's confusion and uncertainty in an industry, the value hound in him is confident he can see what the market has missed, especially if many investors are waiting for the smoke to clear. There's a whole bunch of uncertainty in the health-care arena these days, so Mike has his eye on what he characterizes as a health-care-reform fun pack: two companies he's watching and one he's already bought.
Testing the blockbusters
Pharmaceutical Products Development
The pharmaceutical industry is murky these days as a result of an unsure economy, pending patent expirations, and merger and acquisition activity. As a result, pharmaceutical companies curtailed research and development and canceled contracts for work with PPDI, and its financial results have fallen off a cliff. But with tens of billions of dollars in drugs coming off patent over the next several years, big pharma needs to find new blockbusters to replace their revenue stream. Mike is optimistic that PPDI will be the business to help those companies take their drugs from the lab to the pharmacy.
Knees to know
Mike sees the knee-replacement business as essentially a duopoly with Zimmer and Stryker
"It's priced as though cash flow to earnings will never grow again," he says. "The cheapness isn't entirely unwarranted. By virtue of being a pure play on knees, it's more exposed to Medicare reimbursement than Stryker, and health-care reimbursements will decline with the recently passed health-care legislation. But it's an outstanding business and, let's face it, the need for knee replacements isn't declining."
And the one he bought
Still-high unemployment combined with an acquisition that many deemed exceedingly pricey has led to tough times for AMN Healthcare Services
But Mike thinks the acquisition will look much more reasonable in retrospect, and even if it doesn't, the shares still look cheap. Moreover, the company will benefit greatly as the economy improves, and should get a boost from health-care reform. Put it all together, and Mike projects the stock can climb from its current value around $6 to as much as $12 per share. As the Motley Fool Hidden Gems team wrote when they followed Mike's suggestion to buy shares (twice), "Wall Street seems to have abandoned all hope of returns, which is exactly why we think there's still substantial value in AMN, and we're glad to have the opportunity to double down. Often you will get your best returns from adding on dips to stocks you already own."
And that's why it pays to watch. You can make smarter investing decisions with your own version of My Watchlist, new and free from the Fool. Click below to start following one of the stocks mentioned above:
Roger Friedman doesn't own shares of any companies mentioned, but they're all now on his watchlist. Stryker is a Motley Fool Inside Value pick. Pharmaceutical Product Development is a Motley Fool Stock Advisor choice. The Fool owns shares of AMN Healthcare Services. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
More from The Motley Fool
The Top 3 Dividend Aristocrats to Watch in 2018
Big news in the coming year could send these stocks higher or threaten their payouts.
These 3 Stocks Just Raised Their Dividends
There isn't much time left for companies to get in their last payout hikes of 2017. This trio made it with only weeks to spare.
Why Stryker, Ultragenyx Pharmaceutical, and La-Z-Boy Slumped Today
These stocks helped put downward pressure on the market. Find out why.